beta

ACAD

ACADIA Pharmaceuticals Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

	11-06-2018 after market close	08-08-2018 after market close	05-04-2018	02-27-2018 after market close	11-07-2017 after market close	08-08-2017 after market close	05-09-2017 after market close
Actual EPS	-0.5	-0.51	-0.44	-0.55	-0.53	-0.55	-0.72
Consensus EPS	-0.58	-0.45	-0.56	-0.58	-0.63	-0.71	-0.73
Estimated EPS	-0.58	-0.45	-0.56	-0.58	-0.63	-0.71	-0.73
Number of Estimates	6	5	5	6	6	6	5
EPS Surprise	$0.08	-$0.06	$0.12	$0.03	$0.10	$0.16	$0.01

Stats

Summary

ACADIA Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. It aims to discover small molecule drugs to address Parkinson's, Alzheimer's and schizophrenia.

Market Cap: 3.99 Billion

Primary Exchange: Nasdaq Global Select

Website: http://www.acadia-pharm.com

Shares Outstanding: 124 Million

Float: 124 Million

Dividend: 0.0 (0.0%)

Beta: 3.424601

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 11.8 Million

Ethical Flags

Longest drawdown: 855 trading days

From: 2015-07-17 To: 2018-12-07

Lowest Point:

Daily Insider Ratings Round Up 12/4/18

via: SeekingAlpha at 2018-12-06 11:29:00:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 12/4/18

via: SeekingAlpha at 2018-12-06 11:29:00:000

Daily Insider Ratings Round Up 12/4/18

via: SeekingAlpha at 2018-12-06 11:29:00:000

Acadia: Poised To Turn

via: SeekingAlpha at 2018-12-04 04:47:22:000

Acadia ( ACAD ) dodged the worst of the undertow that has swamped so many speculative biotechs in recent months. Then, a late October announcement of a shelf stock offering threatened to drag it down with other laggards. The dip was short-lived. Acadia is a stock that carries significant ris… read more...

Acadia: Poised To Turn

via: SeekingAlpha at 2018-12-04 04:47:22:000

ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

via: Business Wire at 2018-11-30 16:05:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten publ… read more...

ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

via: Business Wire at 2018-11-30 16:05:00:000

ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

via: Business Wire at 2018-11-30 16:05:00:000

ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

via: Business Wire at 2018-11-30 16:05:00:000

Acadia up 13% premarket on Baker Bros. stake

via: SeekingAlpha at 2018-11-28 09:16:28:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) is up 13% premarket on robust volume. A tweet from Open Outcrier states that Baker Brothers has accumulated a large stake. More news on: ACADIA Pharmaceuticals Inc., Healthcare stocks news, Read more … read more...

Acadia up 13% premarket on Baker Bros. stake

via: SeekingAlpha at 2018-11-28 09:16:28:000

ACADIA Pharmaceuticals prices equity offering

via: SeekingAlpha at 2018-11-28 05:27:57:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) has priced public offering of 16,176,471 shares of its common stock at $17.00 per share, gross proceeds expected to be ~$275M. More news on: ACADIA Pharmaceuticals Inc., Healthcare stocks news, Read more … read more...

ACADIA Pharmaceuticals prices equity offering

via: SeekingAlpha at 2018-11-28 05:27:57:000

ACADIA Pharmaceuticals Prices Public Offering of Common Stock

via: Business Wire at 2018-11-27 21:20:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 16,176,… read more...

ACADIA Pharmaceuticals Prices Public Offering of Common Stock

via: Business Wire at 2018-11-27 21:20:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 16,176,… read more...

ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock

via: Business Wire at 2018-11-26 16:08:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it intends to offer and sell, in an underwritten pub… read more...

ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock

via: Business Wire at 2018-11-26 16:08:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it intends to offer and sell, in an underwritten pub… read more...

Acadia Pharmaceuticals Is A Promising Buy In 2018

via: SeekingAlpha at 2018-11-19 08:04:13:000

Headquartered in Tennessee, Acadia Pharmaceuticals ( ACAD ) has been making rapid advances on financial, operational, and clinical fronts. In the third quarter , the company reported revenues of $58.3 million, a robust 64% rise on a YoY basis. The company has updated its fiscal year 2018 re… read more...

Acadia Pharmaceuticals Is A Promising Buy In 2018

via: SeekingAlpha at 2018-11-19 08:04:13:000

Acadia Pharmaceuticals Is A Promising Buy In 2018

via: SeekingAlpha at 2018-11-19 08:04:13:000

Leerink sees 34% upside in Allergan in premarket analyst action

via: SeekingAlpha at 2018-11-13 08:20:25:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Market Perform rating at Leerink Partners. More news on: ACADIA Pharmaceuticals Inc., AC Immune SA, Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Leerink sees 34% upside in Allergan in premarket analyst action

via: SeekingAlpha at 2018-11-13 08:20:25:000

Leerink sees 34% upside in Allergan in premarket analyst action

via: SeekingAlpha at 2018-11-13 08:20:25:000

ACADIA Pharmaceuticals Inc. 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-11-08 19:59:08:000

The following slide deck was published by ACADIA Pharmaceuticals Inc. in conjunction with their 2018 Q3 earnings Read more … read more...

ACADIA Pharmaceuticals Inc. 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-11-08 19:59:08:000

The following slide deck was published by ACADIA Pharmaceuticals Inc. in conjunction with their 2018 Q3 earnings Read more … read more...

ACADIA Pharmaceuticals Inc. 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-11-08 19:59:08:000

The following slide deck was published by ACADIA Pharmaceuticals Inc. in conjunction with their 2018 Q3 earnings Read more … read more...

ACADIA Pharmaceuticals Inc. 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-11-08 19:59:08:000

The following slide deck was published by ACADIA Pharmaceuticals Inc. in conjunction with their 2018 Q3 earnings Read more … read more...

ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-07 23:21:08:000

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2018 Results Earnings Conference Call November 06, 2018 05:00 PM ET Executives Elena Ridloff - SVP, IR and Interim CFO Steve Davis - President and CEO Michael Yang - Chief Commercial Officer Dr. Serge Stankovic - Head, R&D Analysts … read more...

ACADIA Pharma beats by $0.08, beats on revenue

via: SeekingAlpha at 2018-11-06 16:10:36:000

ACADIA Pharma (NASDAQ: ACAD ): Q3 GAAP EPS of -$0.50 beats by $0.08 . Revenue of $58.3M (+63.8% Y/Y) beats by $1.99M . Press Release More news on: ACADIA Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, read more...

ACADIA Pharma beats by $0.08, beats on revenue

via: SeekingAlpha at 2018-11-06 16:10:36:000

ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results

via: Business Wire at 2018-11-06 16:05:00:000

-Third Quarter Net Sales Grew to $58.3 Million -Recently Announced Positive Top-line Results from the Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment for Major Depressive Disorder -FDA Issued Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID &#xA… read more...

ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results

via: Business Wire at 2018-11-06 16:05:00:000

A Migrating Biotech Bear

via: SeekingAlpha at 2018-11-06 08:39:35:000

Biotech Pulse Biotechnology is in a Bear Market. At least the midcap and smallcap segment of it. The S&P Biotechnology Select Index ( XBI ), which is weighted towards the midcap and smallcap companies, has dropped 24% from its high recorded on August 30 to its lowest point past Monda… read more...

A Migrating Biotech Bear

via: SeekingAlpha at 2018-11-06 08:39:35:000

Notable earnings after Tuesday's close

via: SeekingAlpha at 2018-11-05 17:35:37:000

ACAD , AAXN , AIZ , APEI , ASH , BEL , BOLD , BWXT , CHUY , COHR , CPE , CSLT , CUTR , CWH , DAR , DATA , DIOD , DK , DOOR , DPLO , DVN , DXC , DXCM , EGN , ENLC , ENLK , ENPH , ETSY , EVH , EVRI , FANG , FIVN , FTK , FTR , G , GDDY , GHDX , GLUU , HAL… read more...

Services, Consumer and Technology earnings lift futures higher

via: SeekingAlpha at 2018-10-31 09:23:52:000

LSC Communications (NYSE: LKSD ) +31% on Q3 result . More news on: LSC Communications, Inc., Mitek Systems Inc., KemPharm, Top stock market news, Stocks on the move, , Read more … read more...

Services, Consumer and Technology earnings lift futures higher

via: SeekingAlpha at 2018-10-31 09:23:52:000

LSC Communications (NYSE: LKSD ) +31% on Q3 result . More news on: LSC Communications, Inc., Mitek Systems Inc., KemPharm, Top stock market news, Stocks on the move, , Read more … read more...

Services, Consumer and Technology earnings lift futures higher

via: SeekingAlpha at 2018-10-31 09:23:52:000

LSC Communications (NYSE: LKSD ) +31% on Q3 result . More news on: LSC Communications, Inc., Mitek Systems Inc., KemPharm, Top stock market news, Stocks on the move, , Read more … read more...

ACADIA Pharma up 11% premarket on positive mid-stage pimavanserin data in MDD

via: SeekingAlpha at 2018-10-31 07:11:34:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) is up 11% premarket on light volume in response to the successful outcome of a Phase 2 clinical trial, CLARITY , evaluating pimavanserin in patients with major depressive disorder (MDD) who failed to respond adequately to a stable dose of… read more...

ACADIA Pharma up 11% premarket on positive mid-stage pimavanserin data in MDD

via: SeekingAlpha at 2018-10-31 07:11:34:000

ACADIA Pharma up 11% premarket on positive mid-stage pimavanserin data in MDD

via: SeekingAlpha at 2018-10-31 07:11:34:000

ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)

via: Business Wire at 2018-10-31 06:30:00:000

- Pimavanserin met primary endpoint with statistically significant overall improvement in HAMD-17 total score compared to placebo (p=0.039) - Pimavanserin met key secondary endpoint with statistically significant overall improvement in Sheehan Disability Scale compared to placebo (p=0…. read more...

ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)

via: Business Wire at 2018-10-31 06:30:00:000

ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)

via: Business Wire at 2018-10-31 06:30:00:000

ACADIA Pharmaceuticals Announces Executive Leadership Change

via: Business Wire at 2018-10-29 16:35:00:000

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that Todd S. Young, Executive Vice President and Chief Financial Officer, will be leaving the organization effective October 31, 2018 to join another healthcare company. Elena Ridloff, CFA, Senior Vice President, Investor Relations w… read more...

ACADIA Pharmaceuticals Announces Executive Leadership Change

via: Business Wire at 2018-10-29 16:35:00:000

This Stock Reset Requires Patience

via: SeekingAlpha at 2018-10-29 15:53:28:000

Halloween is here, but the goblins seem to have lost their way into the stock market. And they're creating havoc! The relentless volatility and a drip of near-daily 1-2% decline are darkening investor confidence and making it a month of terror. What started as a question of whether the Feder… read more...

This Stock Reset Requires Patience

via: SeekingAlpha at 2018-10-29 15:53:28:000

Acadia Pharmaceuticals: Continued Upside Ahead Through Sales Growth And Clinical Catalysts

via: SeekingAlpha at 2018-10-23 22:01:13:000

Shares of ACADIA Pharmaceuticals ( ACAD ) have shed roughly a third of their value over the past three years. Even after the recent rebound, the stock price is in the red by about 25% in 2018. While shorts certainly profited with ominous CNN headline raising concerns about patient deaths and… read more...

Acadia Pharmaceuticals: Continued Upside Ahead Through Sales Growth And Clinical Catalysts

via: SeekingAlpha at 2018-10-23 22:01:13:000

Acadia Pharmaceuticals: Continued Upside Ahead Through Sales Growth And Clinical Catalysts

via: SeekingAlpha at 2018-10-23 22:01:13:000

ACADIA Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 6, 2018

via: Business Wire at 2018-10-23 09:00:00:000

ACADIA to Host Conference Call and Webcast on Tuesday, November 6, 2018, at 5:00 p.m. Eastern Time ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in centr… read more...

Biotech Stocks Bloodied But Can Now Drive M&A

via: SeekingAlpha at 2018-10-19 12:04:35:000

The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y… read more...

Biotech Stocks Bloodied But Can Now Drive M&A

via: SeekingAlpha at 2018-10-19 12:04:35:000

Biotech Stocks Bloodied But Can Now Drive M&A

via: SeekingAlpha at 2018-10-19 12:04:35:000

Biotech Stocks Bloodied But Can Now Drive M&A

via: SeekingAlpha at 2018-10-19 12:04:35:000

ACADIA Pharmaceuticals (ACAD) Presents At Cantor Global Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-10-03 14:45:56:000

The following slide deck was published by ACADIA Pharmaceuticals Inc. in conjunction with this Read more … read more...

ACADIA Pharmaceuticals (ACAD) Presents At Cantor Global Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-10-03 14:45:56:000

The following slide deck was published by ACADIA Pharmaceuticals Inc. in conjunction with this Read more … read more...

ACADIA Pharmaceuticals (ACAD) Presents At Cantor Global Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-10-03 14:45:56:000

The following slide deck was published by ACADIA Pharmaceuticals Inc. in conjunction with this Read more … read more...

Acadia's Big Scores

via: SeekingAlpha at 2018-09-27 12:18:12:000

This is an article that has taken too long to write. The problem is that I get sidetracked by Geron's fascinating story, again and again . Initially, I was going to review how Acadia ( ACAD ) had solid plans for addressing its NUPLAZID troubles. Now with the recent favorable FDA analys… read more...

Acadia's Big Scores

via: SeekingAlpha at 2018-09-27 12:18:12:000

Acadia's Big Scores

via: SeekingAlpha at 2018-09-27 12:18:12:000

ACADIA Pharmaceuticals Announces Executive Appointments to Lead Medical Affairs and Science

via: Business Wire at 2018-09-26 09:00:00:000

-Robert Kaper, M.D., named Senior Vice President, Global Head of Medical Affairs -Eliseo Salinas, M.D., M.Sc., named Senior Vice President, Chief Scientific Officer and Head of External Innovation ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on … read more...

Daily Insider Ratings Round Up 9/24/18

via: SeekingAlpha at 2018-09-25 16:24:10:000

Acadia Survives CNN 'Bear Attack'

via: SeekingAlpha at 2018-09-25 15:53:55:000

A single death is a tragedy, a million deaths is a statistic . Joseph Stalin Last week one of the biggest gainers in the market was Acadia Pharmaceuticals ( ACAD ). These beaten down biopharma shares rose some 40% in trading last week as the FDA stated the agency foun… read more...

ACADIA Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference on October 2, 2018

via: Business Wire at 2018-09-25 09:00:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 2018 Cantor Global Healthcare Con… read more...

Acadia Receives A Rubber Stamp From FDA On Nuplazid Risk-Benefit Profile

via: SeekingAlpha at 2018-09-21 11:58:23:000

On Thursday, Acadia Pharmaceuticals ( ACAD ) stock closed higher by 26% to $19.11 per share on the back of a positive development from the FDA . This involves the prior safety issues that were brought up over patients being treated with Nuplazid. The final conclusion from the FDA proved… read more...

Acadia Receives A Rubber Stamp From FDA On Nuplazid Risk-Benefit Profile

via: SeekingAlpha at 2018-09-21 11:58:23:000

Acadia Receives A Rubber Stamp From FDA On Nuplazid Risk-Benefit Profile

via: SeekingAlpha at 2018-09-21 11:58:23:000

Acadia Receives A Rubber Stamp From FDA On Nuplazid Risk-Benefit Profile

via: SeekingAlpha at 2018-09-21 11:58:23:000

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2018-09-21 09:22:53:000

GLT +49% . More news on: Glatfelter, DAVIDs TEA, Oasmia Pharmaceutical, Stocks on the move, , Top stock market news, Read more … read more...

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2018-09-21 09:22:53:000

GLT +49% . More news on: Glatfelter, DAVIDs TEA, Oasmia Pharmaceutical, Stocks on the move, , Top stock market news, Read more … read more...

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2018-09-21 09:22:53:000

GLT +49% . More news on: Glatfelter, DAVIDs TEA, Oasmia Pharmaceutical, Stocks on the move, , Top stock market news, Read more … read more...

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2018-09-21 09:22:53:000

GLT +49% . More news on: Glatfelter, DAVIDs TEA, Oasmia Pharmaceutical, Stocks on the move, , Top stock market news, Read more … read more...

FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson's Disease Psychosis

via: Business Wire at 2018-09-20 17:15:00:000

- FDA analysis finds no new or unexpected safety risks associated with NUPLAZID - Patients taking NUPLAZID for Parkinsons disease psychosis should continue to use it as prescribed by their health care provider - FDA also reminds heath care providers that no other antipsychotic m… read more...

Acadia Pharma up 12% on favorable FDA analysis on Nuplazid

via: SeekingAlpha at 2018-09-20 12:37:59:000

ACADIA Pharmaceuticals ( ACAD +12.1% ) is up on average volume in apparent response to an FDA post stating the it found no new safety risks associated with NUPLAZID (pimavanserin), approved in the U.S. in April 2016 for Parkinson's disease-associated psychosis. More news on: ACADIA Pha… read more...

ACADIA PHARMACEUTICALS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: Business Wire at 2018-09-16 22:50:00:000

ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD). Investor losses must relate to purchases of the… read more...

ACADIA PHARMACEUTICALS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: Business Wire at 2018-09-16 22:50:00:000

ACADIA PHARMACEUTICALS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: Business Wire at 2018-09-16 22:50:00:000

ACADIA PHARMA 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: Business Wire at 2018-09-14 22:50:00:000

Kahn Swick & Foti, LLC (KSF) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until September 17, 2018 to file lead plaintiff applications in a securities class action la… read more...

ACADIA PHARMA 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: Business Wire at 2018-09-14 22:50:00:000

MONDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-09-13 12:39:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against ACADIA Pharmaceuticals Inc. (ACADIA or the Company) (NASDAQ: ACAD ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

MONDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-09-13 12:39:00:000

Investors: The Law Offices of Howard G. Smith Reminds Investors of Lead Plaintiff Deadline in the Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. (ACAD)

via: Business Wire at 2018-09-12 19:21:00:000

Law Offices of Howard G. Smithreminds investors of the September 17, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased ACADIA Pharmaceuticals Inc. (ACADIA or the Company) (NASDAQ: ACAD ) secu… read more...

Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer's Disease Psychosis and Parkinson's Disease Psychosis Published in The Journal of Prevention of Alzheimer's Disease Suggest Potential for Treating Dementia-Related Psychosis

via: Business Wire at 2018-09-10 09:00:00:000

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) announced today publication of additional data from a Phase 2 single center, double-blind, placebo-controlled study to examine the safety and efficacy of pimavanserin for the treatment of psychosis in Alzheimers Disease Psychosis in The Jou… read more...

Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer's Disease Psychosis and Parkinson's Disease Psychosis Published in The Journal of Prevention of Alzheimer's Disease Suggest Potential for Treating Dementia-Related Psychosis

via: Business Wire at 2018-09-10 09:00:00:000

Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer's Disease Psychosis and Parkinson's Disease Psychosis Published in The Journal of Prevention of Alzheimer's Disease Suggest Potential for Treating Dementia-Related Psychosis

via: Business Wire at 2018-09-10 09:00:00:000

ACADIA Pharmaceuticals to Present at the Morgan Stanley 16th Annual Global Healthcare Conference on September 13, 2018

via: Business Wire at 2018-09-04 09:00:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Morgan Stanley 16 th Annual Glob… read more...

ACADIA Pharmaceuticals to Present at the Morgan Stanley 16th Annual Global Healthcare Conference on September 13, 2018

via: Business Wire at 2018-09-04 09:00:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Morgan Stanley 16 th Annual Glob… read more...

ACADIA Pharmaceuticals to Present at the Morgan Stanley 16th Annual Global Healthcare Conference on September 13, 2018

via: Business Wire at 2018-09-04 09:00:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Morgan Stanley 16 th Annual Glob… read more...

ACAD NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.; Important Sept. 17 Deadline - ACAD

via: PR Newswire at 2018-09-01 08:20:00:000

NEW YORK , Sept. 1, 2018 /PRNewswire/ --Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) between April 29, 2016 and July 9, 2018 , both dates i… read more...

ACAD NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.; Important Sept. 17 Deadline - ACAD

via: PR Newswire at 2018-09-01 08:20:00:000

ACAD NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.; Important Sept. 17 Deadline - ACAD

via: PR Newswire at 2018-09-01 08:20:00:000

September 17th Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.

via: Business Wire at 2018-08-30 19:10:00:000

National securities litigation law firm Glancy Prongay & Murray LLP (GPM)reminds investors of the September 17, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased ACADIA Pharmaceuticals Inc. (&… read more...

September 17th Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.

via: Business Wire at 2018-08-30 19:10:00:000

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ACADIA Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD

via: PR Newswire at 2018-08-29 18:02:00:000

NEW YORK , Aug. 29, 2018 /PRNewswire/ --Pomerantz LLP announces that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) and certain of its officers. The class action, filed in United States Distric… read more...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ACADIA Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD

via: PR Newswire at 2018-08-29 18:02:00:000

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ACADIA Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD

via: PR Newswire at 2018-08-29 18:02:00:000

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of ACADIA Pharmaceuticals Inc. Investors

via: Business Wire at 2018-08-28 19:45:00:000

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased ACADIA Pharmaceuticals Inc. (ACADIA or the Company) (NASDAQ: ACAD ) securities between April 29, 2016 and July 9, 2018 ,inclu… read more...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 in Acadia Pharmaceuticals, Inc. to Contact the Firm

via: Business Wire at 2018-08-28 18:00:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Acadia Pharmaceuticals, Inc. (Acadia or the Company) (NASDAQ:ACAD) of the September 17, 2018 deadline to seek the role of lead plaintiff in a federal securities class action… read more...

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: Business Wire at 2018-08-24 22:50:00:000

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD), if they purchased the Companys securities be… read more...

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: Business Wire at 2018-08-24 22:50:00:000

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: Business Wire at 2018-08-24 22:50:00:000

SHAREHOLDER ALERT: WeissLaw LLP Investigates Acadia Pharmaceuticals, Inc.

via: PR Newswire at 2018-08-24 13:58:00:000

NEW YORK , Aug. 24, 2018 /PRNewswire/ --WeissLaw LLP, a national class action, shareholder rights law firm with offices in New York , Los Angeles , and Atlanta , announces an investigation of Acadia Pharmaceuticals, Inc. (the "Company" or "ACAD") (NASDAQ: ACAD), its Board of Dire… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-23 08:21:11:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Overweight rating and $25 (79% upside) price target at Cantor Fitzgerald. Shares up 3% premarket. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Halozyme Therapeutics, Inc., Healthcare stocks news,… read more...

Own A Bond Instead Of Ford - Cramer's Lightning Round (8/22/18)

via: SeekingAlpha at 2018-08-23 06:53:52:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, August 22. Bullish Calls XPO Logistics (XPO): CEO Brad Jacobs is doing a great job and the chart for the stock looks good. Dropbox (DBX): The sellers have got it wrong and the company has a gr… read more...

Cramer's lightning round: Pick this stock for a biotech play

via: CNBC at 2018-08-22 18:44:00:000

No summary available. read more...

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: PR Newswire at 2018-08-17 22:50:00:000

NEW ORLEANS , Aug. 17, 2018 /PRNewswire/ --ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against ACADIA Pharmaceuticals Inc. (NasdaqGS: ACA… read more...

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: PR Newswire at 2018-08-17 22:50:00:000

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: PR Newswire at 2018-08-17 22:50:00:000

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: PR Newswire at 2018-08-17 22:50:00:000

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In ACADIA Pharmaceuticals, Inc. To Contact The Firm

via: PR Newswire at 2018-08-17 17:53:00:000

NEW YORK , Aug. 17, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in ACADIA Pharmaceuticals, Inc. ("ACADIA" or the "Company") (NASDAQ:ACAD) of the September 17, 2018 deadline to seek the role of lead plaintiff in a federal secur… read more...

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

via: Business Wire at 2018-08-15 09:36:00:000

The law firm of Kessler Topaz Meltzer & Check, LLP reminds ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) (ACADIA) investors that a securities fraud class action lawsuit has been filed on behalf of purchasers of ACADIA securities between April 29, 2016 and July 9, 2018 , i… read more...

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

via: Business Wire at 2018-08-15 09:36:00:000

What Is Going On At Axovant Sciences?

via: SeekingAlpha at 2018-08-15 09:30:24:000

On February 12, 2018, Axovant Sciences ( AXON ) issued a press release noting changes to the management team and Board of Directors. Dr David Hung retired as CEO and Dr Pavan Cheruvu took his place, among other changes. Three and a half months of radio silence followed. What broke the sile… read more...

What Is Going On At Axovant Sciences?

via: SeekingAlpha at 2018-08-15 09:30:24:000

Acadia: Nuplazid Troubles Boost Roluperidone Prospects

via: SeekingAlpha at 2018-08-11 10:24:32:000

Shares in Minerva ( NERV ) have traded sideways since we introduced their prospects in negative symptoms in schizophrenia nearly a month ago. However, this wasn't associated with no major news. The following article will magnify the relationship between poor Nuplazid news/revenues and Mine… read more...

Acadia: Nuplazid Troubles Boost Roluperidone Prospects

via: SeekingAlpha at 2018-08-11 10:24:32:000

Acadia: Nuplazid Troubles Boost Roluperidone Prospects

via: SeekingAlpha at 2018-08-11 10:24:32:000

Acadia: Nuplazid Troubles Boost Roluperidone Prospects

via: SeekingAlpha at 2018-08-11 10:24:32:000

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: Business Wire at 2018-08-10 22:50:00:000

Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against ACADIA Pharmaceuticals Inc… read more...

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: Business Wire at 2018-08-10 22:50:00:000

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: Business Wire at 2018-08-10 22:50:00:000

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: Business Wire at 2018-08-10 22:50:00:000

ACADIA Pharmaceuticals Inc. 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-08-09 15:54:37:000

The following slide deck was published by ACADIA Pharmaceuticals Inc. in conjunction with their 2018 Q2 earnings Read more … read more...

ACADIA Pharmaceuticals Inc. 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-08-09 15:54:37:000

The following slide deck was published by ACADIA Pharmaceuticals Inc. in conjunction with their 2018 Q2 earnings Read more … read more...

Premarket Losers as of 9:05 am (8/9/2018)

via: SeekingAlpha at 2018-08-09 09:19:18:000

ABIL -24% . More news on: Ability Inc., e.l.f. Beauty, Aqua Metals, Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (8/9/2018)

via: SeekingAlpha at 2018-08-09 09:19:18:000

ABIL -24% . More news on: Ability Inc., e.l.f. Beauty, Aqua Metals, Stocks on the move, , Read more … read more...

ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-08 23:56:06:000

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2018 Earnings Conference Call August 8, 2018 17:00 ET Executives Elena Ridloff - Senior Vice President-Investor Relations Steve Davis - President and Chief Executive Officer Serge Stankovic - Head-Research and Development Michael Yang - Chi… read more...

ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-08 23:56:06:000

ACADIA Q2 miss and softer guidance pressures shares, down 11% after hours

via: SeekingAlpha at 2018-08-08 20:00:03:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) is down 11% after hours on increased volume on the heels of its release of Q2 results that fell shy of consensus . Highlights: More news on: ACADIA Pharmaceuticals Inc., Healthcare stocks news, Earnings news and commentary, Stocks on th… read more...

ACADIA Q2 miss and softer guidance pressures shares, down 11% after hours

via: SeekingAlpha at 2018-08-08 20:00:03:000

After Hours Gainers / Losers (08/08/2018)

via: SeekingAlpha at 2018-08-08 17:40:55:000

Top Gainers: YELP +11.3% . SAIL +10.3%. CVNA +9.8% . MFIN +9.4% . ROKU +9.2% . More news on: Yelp, SailPoint Technologies, Carvana Co., Stocks on the move, , Read more … read more...

ACADIA Pharma misses by $0.06, misses on revenue

via: SeekingAlpha at 2018-08-08 16:06:56:000

ACADIA Pharma (NASDAQ: ACAD ): Q2 EPS of -$0.51 misses by $0.06 . Revenue of $57.1M (+87.3% Y/Y) misses by $1.53M . Shares -7.3% . Press Release More news on: ACADIA Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, read more...

ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results

via: Business Wire at 2018-08-08 16:05:00:000

Second Quarter Net Sales Grew to $57.1 Million, Representing a 17% Sequential Increase Over 1Q18 and 87% Increase Over 2Q17 Announced FDA Approval of New Dosing Formulation and Strength of NUPLAZID (Pimavanserin) Expanded ACADIAs Pipelin… read more...

Notable earnings after Wednesday's close

via: SeekingAlpha at 2018-08-07 17:35:37:000

ACAD , ACTG , ADT , AINV , AMBC , AMPH , ANGI , AOSL , APEI , ATO , AVT , AYX , AZPN , BKNG , BREW , BV , CISN , COLL , CPA , CTL , CVNA , CXW , DNB , DOOR , ECPG , ELF , ENS , EQIX , ETE , ETP , EVRG , FANG , FG , FLO , FLS , FNV , FOXA , FSM , GBDC ,… read more...

Is The FDA Going To Do Anything About Acadia Pharmaceuticals' Nuplazid?

via: SeekingAlpha at 2018-08-07 10:00:00:000

ACADIA Pharmaceuticals Inc. ( ACAD ) is a biopharmaceutical company focused largely on the marketing of Nuplazid (pimavanserin), to treat hallucinations and delusions associated with Parkinson's disease psychosis, and its clinical development in additional indications. There has been some cove… read more...

Intrinsic Value Of Acadia: Deep Dive And Financial Analysis

via: SeekingAlpha at 2018-08-07 09:15:00:000

The stock price of ACADIA Pharmaceutical Inc. ( ACAD ) dropped >60% in the last 9 months from ~40 to 14-ish. A few reasons may explain this dramatic fall including 1) lack of catalyst in terms of clinical readout and market/regulatory events; 2) concerns on sustained revenue growth; 3) nega… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Pharmaceuticals, Inc. To Contact The Firm

via: Business Wire at 2018-08-06 19:10:00:000

ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development and Commercialization of Trofinetide in Rett Syndrome

via: Business Wire at 2018-08-06 17:16:00:000

-ACADIA plans to initiate a Phase 3 study of trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental congenital CNS disorder, in the second half of 2019 -Neuren retains all rights to trofinetide outside of North America -Neuren to receive US $10 million upfront p… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-06 07:57:30:000

Alder Biopharmaceuticals (NASDAQ: ALDR ) initiated with Overweight rating and $28 (47% upside) price target at Piper Jaffray. More news on: Alder Biopharmaceuticals Inc., Global Blood Therapeutics, Sage Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...

ACAD ALERT NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.; Investor Deadline - ACAD

via: Business Wire at 2018-08-04 11:00:00:000

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) between April 29, 2016 and July 9, 2018, both dates inclusive (the Class Period). The laws… read more...

ACAD ALERT NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.; Investor Deadline - ACAD

via: Business Wire at 2018-08-04 11:00:00:000

Investor Alert: Kaplan Fox Announces Investigation Of ACADIA Pharmaceuticals

via: PR Newswire at 2018-08-01 10:29:00:000

NEW YORK , Aug. 1, 2018 /PRNewswire/ --Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("ACADIA" or the "Company") (Nasdaq: ACAD). Investors who purchased ACADIA securities between April 29, 2… read more...

Investor Alert: Kaplan Fox Announces Investigation Of ACADIA Pharmaceuticals

via: PR Newswire at 2018-08-01 10:29:00:000

Investor Alert: Kaplan Fox Announces Investigation Of ACADIA Pharmaceuticals

via: PR Newswire at 2018-08-01 10:29:00:000

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-01 08:05:27:000

Kura Oncology (NASDAQ: KURA ) initiated with Buy rating and $31 (53% upside) price target at H.C. Wainwright. More news on: Kura Oncology, Sensus Healthcare, Sarepta Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-01 08:05:27:000

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-01 08:05:27:000

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed against ACADIA Pharmaceuticals Inc.

via: Business Wire at 2018-07-31 10:15:00:000

The law firm of Kessler Topaz Meltzer & Check, LLP reminds that an investor securities fraud class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) (ACADIA) on behalf of purchasers of ACADIA securities between April 29, 2016 and July 9, 2… read more...

ACADIA Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 8, 2018

via: Business Wire at 2018-07-30 09:00:00:000

ACADIA to Host Conference Call and Webcast on Wednesday, August 8, 2018, at 5:00 p.m. Eastern Time ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in ce… read more...

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: PR Newswire at 2018-07-27 22:50:00:000

NEW ORLEANS , July 27, 2018 /PRNewswire/ --Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana , Charles C. Foti, Jr. , remind investors that they have until September 17, 2018 to file lead plaintiff applications in a securities class actio… read more...

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: PR Newswire at 2018-07-27 22:50:00:000

KASKELA LAW LLC: Shareholder Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

via: Business Wire at 2018-07-26 16:23:00:000

Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) (ACADIA or the Company) on behalf of purchasers of the Companys securities between April 29, 2016 and July 9, 2018 , … read more...

KASKELA LAW LLC: Shareholder Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

via: Business Wire at 2018-07-26 16:23:00:000

RM LAW Announces Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.

via: PR Newswire at 2018-07-26 16:15:00:000

BERWYN, Pa. , July 26, 2018 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased ACADIA Pharmaceuticals Inc. ("ACADIA" or the "Company") (NASDAQ: ACAD) securities between July 17, 2014 and July 3, … read more...

RM LAW Announces Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.

via: PR Newswire at 2018-07-26 16:15:00:000

Biogen slump pressures other biotechs

via: SeekingAlpha at 2018-07-26 10:32:00:000

Biogen's ( BIIB -8.9% ) post-BAN2401 data-stoked drop appears to be affecting some of the other Alzheimer's players. More news on: Biogen Inc., SPDR Biotech ETF, Eisai Co., Ltd. ADR, Healthcare stocks news, Stocks on the move, News on ETFs, Read more … read more...

Biogen slump pressures other biotechs

via: SeekingAlpha at 2018-07-26 10:32:00:000

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against ACADIA Pharmaceuticals Inc. - ACAD

via: PR Newswire at 2018-07-26 10:31:00:000

RADNOR, Pa. , July 26, 2018 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) ("ACADIA") on behalf of purchasers of ACADIA securities betw… read more...

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against ACADIA Pharmaceuticals Inc. - ACAD

via: PR Newswire at 2018-07-26 10:31:00:000

Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Acadia Pharmaceuticals, Inc.

via: Business Wire at 2018-07-25 16:21:00:000

Federman & Sherwood announces that on July 19, 2018, a class action lawsuit was filed in the United States District Court for the Southern District of California against Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD). The complaint alleges violations of federal securities laws, Sections 10(… read more...

Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Acadia Pharmaceuticals Inc.

via: Business Wire at 2018-07-24 11:00:00:000

Robbins Geller Rudman & Dowd LLP ( http://www.rgrdlaw.com/cases/acadiapharm/ ) today announced that a class action has been commenced on behalf of purchasers of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) securities during the period between April 29, 2016 and July 9, 2018 (the C… read more...

New Securities Class Action Filed Against ACADIA Pharmaceuticals, Inc. (ACAD); Block & Leviton Encourages ACADIA Investors to Contact The Firm

via: PR Newswire at 2018-07-24 10:22:00:000

BOSTON , July 24, 2018 /PRNewswire/ -- Block & Leviton LLP ( www.blockesq.com ), a securities litigation firm representing investors nationwide, announces that it has filed a securities fraud class action against ACADIA Pharmaceuticals, Inc. ("ACADIA" or the "Company") (NASDAQ: ACAD) … read more...

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against ACADIA Pharmaceuticals Inc. (ACAD) and Lead Plaintiff Deadline - September 17, 2018

via: PR Newswire at 2018-07-24 10:10:00:000

NEW YORK , July 24, 2018 /PRNewswire/ --Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) and certain of its officers, on behalf … read more...

Robbins Arroyo LLP: Viability of Acadia Pharmaceuticals, Inc. (ACAD) Drug NUPLAZID Questioned by Recently Filed Class Action

via: Business Wire at 2018-07-23 16:43:00:000

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Acadia Pharmaceuticals, Inc. (NASDAQGS: ACAD) have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between April 29, 2016 an… read more...

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-07-23 12:27:00:000

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: Business Wire at 2018-07-20 11:05:00:000

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) between April 29, 2016 and July 9, 2018, both dates inclusive (the Class Period). The lawsu… read more...

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: Business Wire at 2018-07-20 11:05:00:000

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) between April 29, 2016 and July 9, 2018, both dates inclusive (the Class Period). The lawsu… read more...

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

via: Business Wire at 2018-07-20 11:05:00:000

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) between April 29, 2016 and July 9, 2018, both dates inclusive (the Class Period). The lawsu… read more...

Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD)

via: Business Wire at 2018-07-19 21:48:00:000

Glancy Prongay & Murray LLP (GPM)announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California on behalf of persons and entities that acquired ACADIA Pharmaceuticals Inc. (ACADIA or t… read more...

Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD)

via: Business Wire at 2018-07-19 21:48:00:000

Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD)

via: Business Wire at 2018-07-19 21:48:00:000

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-07-19 17:27:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (ACADIA or the Company) (NASDAQ: ACAD ) for violations of 10(b) and 20(a) of the … read more...

ACADIA Pharmaceuticals Announces Appointment of Austin D. Kim as Executive Vice President, General Counsel and Secretary

via: Business Wire at 2018-07-19 16:05:00:000

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Austin D. Kim has joined ACADIA as Executive Vice Pr… read more...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of ACADIA Pharmaceuticals Inc. (ACAD)

via: PR Newswire at 2018-07-19 10:15:00:000

NEW YORK , July 19, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are encouraged to obtain additional i… read more...

ACADIA Pharmaceuticals, Inc. (ACAD) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

via: PR Newswire at 2018-07-18 11:55:00:000

BOSTON , July 18, 2018 /PRNewswire/ --Block & Leviton LLP ( www.blockesq.com ), a securities litigation firm representing investors nationwide, is investigating whether ACADIA Pharmaceuticals, Inc. ("ACADIA" or the "Company") (NASDAQ: ACAD) and certain of its officers and direct… read more...

Playing The Expectations Game In Biotech

via: SeekingAlpha at 2018-07-17 21:11:17:000

Investing in biotech stocks is not for the faint of heart. When positioned in the right biotech stocks, investors can be rewarded with explosive revenue growth and booming profitability from such companies, which generally means that the stock is delivering massive gains. On the other hand, th… read more...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-07-17 17:34:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (ACADIA or ''the Company'') (NASDAQ: ACAD ) for violations of 10(b) and 20(a) of the Securities E… read more...

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against ACADIA Pharmaceuticals Inc. - ACAD

via: Business Wire at 2018-07-17 15:36:00:000

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) resulting from allegations that ACADIA may have issued materially misleading business information to the investi… read more...

Glancy Prongay & Murray LLP Continues Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD)

via: Business Wire at 2018-07-17 10:30:00:000

Glancy Prongay & Murray LLP (GPM) continues its investigation on behalf of ACADIA Pharmaceuticals Inc. (ACADIA or the Company) (NASDAQ: ACAD ) investors concerning the Company and its officers possible violations of federal … read more...

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors

via: Business Wire at 2018-07-16 07:30:00:000

Law Offices of Howard G. Smithcontinues its investigation on behalf of ACADIA Pharmaceuticals Inc. (ACADIA or the Company) (NASDAQ: ACAD ) investors concerning the Company and its officers possible violations of federal securities laws. On April 9, … read more...

Glancy Prongay & Murray LLP Announces Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD)

via: Business Wire at 2018-07-13 16:08:00:000

Glancy Prongay & Murray LLP (GPM) announces that it has commenced an investigation on behalf of ACADIA Pharmaceuticals Inc. (ACADIA or the Company) (NASDAQ: ACAD ) investors concerning the Company and its officers possible v… read more...

Glancy Prongay & Murray LLP Announces Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD)

via: Business Wire at 2018-07-13 16:08:00:000

Glancy Prongay & Murray LLP Announces Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD)

via: Business Wire at 2018-07-13 16:08:00:000

Hagens Berman Alerts Investors in ACADIA Pharmaceuticals Inc. (ACAD) to the Firm's Investigation of Possible Disclosure Violations

via: PR Newswire at 2018-07-11 16:35:00:000

SAN FRANCISCO , July 11, 2018 /PRNewswire/ --Hagens Berman Sobol Shapiro LLP alerts investors in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) to the firm's investigation of possible securities law violations. If you purchased or otherwise acquired ACADIA securities before July… read more...

Hagens Berman Alerts Investors in ACADIA Pharmaceuticals Inc. (ACAD) to the Firm's Investigation of Possible Disclosure Violations

via: PR Newswire at 2018-07-11 16:35:00:000

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors

via: Business Wire at 2018-07-09 21:09:00:000

Law Offices of Howard G. Smithannounces an investigation on behalf of ACADIA Pharmaceuticals Inc. (ACADIA or the Company) (NASDAQ: ACAD ) investors concerning the Company and its officers possible violations of federal securities laws. On Ap… read more...

Acadia down 5% on bearish SIRF article

via: SeekingAlpha at 2018-07-09 10:42:19:000

ACADIA Pharmaceuticals ( ACAD -4.7% ) slips on average volume on the heels of a bearish online article by the Southern Investigative Reporting Foundation (SIRF). More news on: ACADIA Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Alzheimer's players in the green on Biogen news

via: SeekingAlpha at 2018-07-06 10:12:33:000

Most players in the Alzheimer's disease space are in the green after Biogen announced positive mid-stage data on BAN2401. More news on: vTv Therapeutics, Tonix Pharmaceuticals Holding Corp., ACADIA Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Alzheimer's players in the green on Biogen news

via: SeekingAlpha at 2018-07-06 10:12:33:000

Alzheimer's players in the green on Biogen news

via: SeekingAlpha at 2018-07-06 10:12:33:000

Your Daily Pharma Scoop: Spectrum Trial Proceeds, AzurRx Moves To Phase 3, Aptose Jumps

via: SeekingAlpha at 2018-07-02 07:20:07:000

Stocks in News: SPPI, AZRX Spectrum reports second late-stage Rolontis trial meets primary endpoint Discussion : Second Phase 3 trial of Spectrum Pharmaceuticals ( SPPI ) Rolontis met primary efficacy endpoint. The endpoint was non-inferiority in duration of severe neutropenia… read more...

Your Daily Pharma Scoop: Spectrum Trial Proceeds, AzurRx Moves To Phase 3, Aptose Jumps

via: SeekingAlpha at 2018-07-02 07:20:07:000

Your Daily Pharma Scoop: Spectrum Trial Proceeds, AzurRx Moves To Phase 3, Aptose Jumps

via: SeekingAlpha at 2018-07-02 07:20:07:000

Premarket Gainers as of 9:05 am (6/29/2018)

via: SeekingAlpha at 2018-06-29 09:15:58:000

GEMP +114% asGemcabene drug candidate met its primary endpoint . More news on: Gemphire Therapeutics, Echelon Corporation, Dermira, News on the U.S. economy, Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am (6/29/2018)

via: SeekingAlpha at 2018-06-29 09:15:58:000

Premarket Gainers as of 9:05 am (6/29/2018)

via: SeekingAlpha at 2018-06-29 09:15:58:000

Acadia Pharma +12% after FDA approves dosing, strength for Nuplazid

via: SeekingAlpha at 2018-06-29 08:36:30:000

Acadia Pharmaceuticals (NASDAQ: ACAD ) +12.1% premarket after announcing Food and Drug Administration approval of a new capsule dose formulation and new tablet strength of Nuplazid (pimavanserin) for treatment of patients experiencing hallucinations and delusions associated with Par… read more...

Acadia Pharma +12% after FDA approves dosing, strength for Nuplazid

via: SeekingAlpha at 2018-06-29 08:36:30:000

Acadia Pharma +12% after FDA approves dosing, strength for Nuplazid

via: SeekingAlpha at 2018-06-29 08:36:30:000

ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID&#xAE; (Pimavanserin)

via: Business Wire at 2018-06-29 07:30:00:000

New Dosing Formulation and Strength Address Needs in Treating Patients with Hallucinations and Delusions Associated with Parkinsons Disease Psychosis ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced FDA approval of a new capsule dose formulation and a new … read more...

ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID&#xAE; (Pimavanserin)

via: Business Wire at 2018-06-29 07:30:00:000

ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID&#xAE; (Pimavanserin)

via: Business Wire at 2018-06-29 07:30:00:000

Acadia Pharmaceuticals: What Investors Can Expect From This Grower?

via: SeekingAlpha at 2018-06-21 03:01:39:000

Entrepreneurs are great at dealing with uncertainty and also very good at minimizing risk. That's the classic great entrepreneur. - Mohnish Pabrai Despite the strong performance of Integrated BioSci Investing , we have a good mix of robust winners and some losers. This is because investin… read more...

Acadia Pharmaceuticals: What Investors Can Expect From This Grower?

via: SeekingAlpha at 2018-06-21 03:01:39:000

Acadia Pharmaceuticals: What Investors Can Expect From This Grower?

via: SeekingAlpha at 2018-06-21 03:01:39:000

Acadia Pharma down 9%

via: SeekingAlpha at 2018-06-13 15:36:39:000

ACADIA Pharmaceuticals ( ACAD -8.8% ) slumps almost 40% higher volume following its corporate presentation at the Goldman Sachs Healthcare Conference. More news on: ACADIA Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Acadia Pharma down 9%

via: SeekingAlpha at 2018-06-13 15:36:39:000

Acadia Pharma down 9%

via: SeekingAlpha at 2018-06-13 15:36:39:000

ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 20, 2018

via: Business Wire at 2018-06-13 09:00:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the JMP Securities Life Sciences Conf… read more...

ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 20, 2018

via: Business Wire at 2018-06-13 09:00:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the JMP Securities Life Sciences Conf… read more...

ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 20, 2018

via: Business Wire at 2018-06-13 09:00:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the JMP Securities Life Sciences Conf… read more...

ACADIA Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on June 13, 2018

via: Business Wire at 2018-06-06 09:00:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Goldman Sachs 39 th Annual Globa… read more...

ACADIA Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on June 13, 2018

via: Business Wire at 2018-06-06 09:00:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Goldman Sachs 39 th Annual Globa… read more...

ACADIA Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on June 13, 2018

via: Business Wire at 2018-06-06 09:00:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Goldman Sachs 39 th Annual Globa… read more...

Oryzon Genomics commences mid-stage study of Alzheimer's candidate

via: SeekingAlpha at 2018-05-14 12:27:31:000

Spanish biotech Oryzon Genomics announces that enrollment is underway in a Phase 2b clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: vTv Therapeutics, Biogen Inc., Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, … read more...

Oryzon Genomics commences mid-stage study of Alzheimer's candidate

via: SeekingAlpha at 2018-05-14 12:27:31:000

ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018

via: Business Wire at 2018-05-08 09:00:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch Hea… read more...

ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018

via: Business Wire at 2018-05-08 09:00:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch Hea… read more...

Acadia: Damn The Torpedoes, Full Speed Ahead

via: SeekingAlpha at 2018-05-07 08:32:10:000

America's first naval rear admiral, David Farragut, is credited with the memorable command: " damn the torpedoes full speed ahead ". His bold attack on the port of New Orleans during the civil war is the stuff of legend. Acadia's (NASDAQ: ACAD ) Q1, 2018 earnings CC , exemplifies just such … read more...

Acadia: Damn The Torpedoes, Full Speed Ahead

via: SeekingAlpha at 2018-05-07 08:32:10:000

ACADIA Pharmaceuticals' (ACAD) CEO Steve Davis on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-04 15:07:13:000

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2018 Earnings Conference Call May 04, 2018 8:30 AM ET Executives Elena Ridloff Senior Vice President-Investor Relations Steve Davis President and Chief Executive Officer Serge Stankovic Head-Research and Development… read more...

ACADIA Pharmaceuticals' (ACAD) CEO Steve Davis on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-04 15:07:13:000

Premarket Gainers as of 9:05 am (05/04/2018)

via: SeekingAlpha at 2018-05-04 09:17:08:000

CREG +31% . More news on: China Recycling Energy Corporation, Portola Pharmaceuticals, Euro Tech Holdings Company Limited, , Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am (05/04/2018)

via: SeekingAlpha at 2018-05-04 09:17:08:000

CREG +31% . More news on: China Recycling Energy Corporation, Portola Pharmaceuticals, Euro Tech Holdings Company Limited, , Stocks on the move, Read more … read more...

Acadia Pharma Q1 Nuplazid sales $48.9M; shares up 5% premarket

via: SeekingAlpha at 2018-05-04 08:02:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) Q1 results ($M): NUPLAZID sales: 48.9 (+219.6%).Consensus view was $47.1M. More news on: ACADIA Pharmaceuticals Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Acadia Pharma Q1 Nuplazid sales $48.9M; shares up 5% premarket

via: SeekingAlpha at 2018-05-04 08:02:38:000

ACADIA Pharma beats by $0.12, beats on revenue

via: SeekingAlpha at 2018-05-04 07:32:01:000

ACADIA Pharma (NASDAQ: ACAD ): Q1 EPS of -$0.44 beats by $0.12 . More news on: ACADIA Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

ACADIA Pharma beats by $0.12, beats on revenue

via: SeekingAlpha at 2018-05-04 07:32:01:000

ACADIA Pharma (NASDAQ: ACAD ): Q1 EPS of -$0.44 beats by $0.12 . More news on: ACADIA Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results

via: Business Wire at 2018-05-04 07:30:00:000

Strong Performance for NUPLAZID in First Quarter 2018 First Quarter Net Sales Grew to $48.9 Million, Representing a 12% Sequential Increase Over 4Q17 and 220% Increase Over 1Q17 ACADIA Reiterates 2018 Net Sales Guidance of $255 Million to $270 … read more...

ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results

via: Business Wire at 2018-05-04 07:30:00:000

Notable earnings before Friday's open

via: SeekingAlpha at 2018-05-03 17:30:43:000

ABR , ACAD , AGIO , AON , ASIX , AXL , BABA , BCC , BPL , CBOE , CELG , CIO , CNP , DOC , ESNT , GEL , GLOG , GOGO , HMSY , IDXX , IMGN , IONS , ITT , LCII , LNG , LPNT , NJR , NWL , ROCK , RUTH , STWD , TRTN , TWI , VER , VIRT , VST , WPC For Seekin… read more...

Notable earnings before Friday's open

via: SeekingAlpha at 2018-05-03 17:30:43:000

ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations

via: Business Wire at 2018-05-02 09:00:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Elena Ridloff, CFA, has been appointed to the newly … read more...

ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations

via: Business Wire at 2018-05-02 09:00:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Elena Ridloff, CFA, has been appointed to the newly … read more...

ACADIA Pharma (ACAD) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-01-10 13:39:39:000

The following slide deck was published by ACADIA Pharmaceuticals Inc. in conjunction with this Read more … read more...

ACADIA Pharma (ACAD) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-01-10 13:39:39:000

The following slide deck was published by ACADIA Pharmaceuticals Inc. in conjunction with this Read more … read more...

ACADIA Pharma (ACAD) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-01-10 13:39:39:000

The following slide deck was published by ACADIA Pharmaceuticals Inc. in conjunction with this Read more … read more...

ACADIA Pharma (ACAD) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-01-10 13:39:39:000

The following slide deck was published by ACADIA Pharmaceuticals Inc. in conjunction with this Read more … read more...

ACADIA Pharma (ACAD) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-01-10 13:39:39:000

The following slide deck was published by ACADIA Pharmaceuticals Inc. in conjunction with this Read more … read more...

ACADIA Pharmaceuticals: Due For A Rebound

via: SeekingAlpha at 2018-01-08 05:39:09:000

After topping over $40 a share in October, shares of ACADIA Pharmaceuticals ( ACAD ) fell towards yearly lows ahead of the third-quarter earnings results. Though the stock is slowly recovering from the sell-off, it has multiple positive catalysts ahead that may reward its loyal shareholders … read more...

ACADIA Pharmaceuticals: Due For A Rebound

via: SeekingAlpha at 2018-01-08 05:39:09:000

ACADIA Pharmaceuticals: Due For A Rebound

via: SeekingAlpha at 2018-01-08 05:39:09:000

ACADIA Pharmaceuticals: Due For A Rebound

via: SeekingAlpha at 2018-01-08 05:39:09:000

ACADIA Pharmaceuticals: Due For A Rebound

via: SeekingAlpha at 2018-01-08 05:39:09:000

Acadia Remains Significantly Undervalued

via: SeekingAlpha at 2018-01-06 00:20:34:000

It was a disappointing 2017 for Acadia ( ACAD ) considering that the IBB ended up posting gains of more than 20% for the year and even the broader market finished sharply higher. Acadia did end the year in green but those gains were dwarfed by the performance of the IBB. I last covered Acadi… read more...

Acadia Remains Significantly Undervalued

via: SeekingAlpha at 2018-01-06 00:20:34:000

Acadia Remains Significantly Undervalued

via: SeekingAlpha at 2018-01-06 00:20:34:000

Acadia Remains Significantly Undervalued

via: SeekingAlpha at 2018-01-06 00:20:34:000

Acadia Remains Significantly Undervalued

via: SeekingAlpha at 2018-01-06 00:20:34:000

ACADIA Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018

via: Business Wire at 2018-01-02 09:00:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 36 th Annual J.P. Morgan Healthc… read more...

ACADIA Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018

via: Business Wire at 2018-01-02 09:00:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 36 th Annual J.P. Morgan Healthc… read more...

ACADIA Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018

via: Business Wire at 2018-01-02 09:00:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 36 th Annual J.P. Morgan Healthc… read more...

ACADIA Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018

via: Business Wire at 2018-01-02 09:00:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 36 th Annual J.P. Morgan Healthc… read more...

ACADIA Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018

via: Business Wire at 2018-01-02 09:00:00:000

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 36 th Annual J.P. Morgan Healthc… read more...

Heading Into 2018 - With Cautious Optimism

via: SeekingAlpha at 2017-12-19 14:20:38:000

This is my first article on SA, a site that has bullied itself into my daily routine for over 3 years now. Background - I began investing at the ripe ole age of 12 (now 36) with a $250 investment in American Fundamental Investors Fund after I unfortunately let my broker talk me out of investin… read more...

Heading Into 2018 - With Cautious Optimism

via: SeekingAlpha at 2017-12-19 14:20:38:000

Heading Into 2018 - With Cautious Optimism

via: SeekingAlpha at 2017-12-19 14:20:38:000

Heading Into 2018 - With Cautious Optimism

via: SeekingAlpha at 2017-12-19 14:20:38:000

Heading Into 2018 - With Cautious Optimism

via: SeekingAlpha at 2017-12-19 14:20:38:000

ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate Development

via: Business Wire at 2017-12-13 09:00:00:000

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Damien McDevitt, Ph.D., has joined ACADIA as Senior … read more...

ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate Development

via: Business Wire at 2017-12-13 09:00:00:000

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Damien McDevitt, Ph.D., has joined ACADIA as Senior … read more...

ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate Development

via: Business Wire at 2017-12-13 09:00:00:000

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Damien McDevitt, Ph.D., has joined ACADIA as Senior … read more...

ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate Development

via: Business Wire at 2017-12-13 09:00:00:000

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Damien McDevitt, Ph.D., has joined ACADIA as Senior … read more...

ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate Development

via: Business Wire at 2017-12-13 09:00:00:000

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Damien McDevitt, Ph.D., has joined ACADIA as Senior … read more...

Positive Market In 2017 - Cramer's Mad Money (12/11/17)

via: SeekingAlpha at 2017-12-12 07:38:14:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, December 11. What's the reason behind the market's endless rally? "Stocks have indeed come very far, very fast, we're right on the cusp of multiple rate hikes, there was a terrorist attack in Times … read more...

Positive Market In 2017 - Cramer's Mad Money (12/11/17)

via: SeekingAlpha at 2017-12-12 07:38:14:000

Positive Market In 2017 - Cramer's Mad Money (12/11/17)

via: SeekingAlpha at 2017-12-12 07:38:14:000

Positive Market In 2017 - Cramer's Mad Money (12/11/17)

via: SeekingAlpha at 2017-12-12 07:38:14:000

Positive Market In 2017 - Cramer's Mad Money (12/11/17)

via: SeekingAlpha at 2017-12-12 07:38:14:000

Cramer Remix: Acadia is the most volatile stock I've ever covered - and it's worth speculating on

via: CNBC at 2017-12-11 18:59:00:000

No summary available. read more...

Cramer Remix: Acadia is the most volatile stock I've ever covered - and it's worth speculating on

via: CNBC at 2017-12-11 18:59:00:000

No summary available. read more...

Cramer Remix: Acadia is the most volatile stock I've ever covered - and it's worth speculating on

via: CNBC at 2017-12-11 18:59:00:000

No summary available. read more...

Cramer Remix: Acadia is the most volatile stock I've ever covered - and it's worth speculating on

via: CNBC at 2017-12-11 18:59:00:000

No summary available. read more...

Cramer Remix: Acadia is the most volatile stock I've ever covered - and it's worth speculating on

via: CNBC at 2017-12-11 18:59:00:000

No summary available. read more...

Your Daily Pharma Scoop: Acadia Valuation, Galectin Plunges, Revance Positive Result

via: SeekingAlpha at 2017-12-06 04:24:34:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day ea… read more...

Your Daily Pharma Scoop: Acadia Valuation, Galectin Plunges, Revance Positive Result

via: SeekingAlpha at 2017-12-06 04:24:34:000

Your Daily Pharma Scoop: Acadia Valuation, Galectin Plunges, Revance Positive Result

via: SeekingAlpha at 2017-12-06 04:24:34:000

Your Daily Pharma Scoop: Acadia Valuation, Galectin Plunges, Revance Positive Result

via: SeekingAlpha at 2017-12-06 04:24:34:000

Your Daily Pharma Scoop: Acadia Valuation, Galectin Plunges, Revance Positive Result

via: SeekingAlpha at 2017-12-06 04:24:34:000

Can Acadia Pharmaceuticals Be A Prudent Bet For Long-Term Investors?

via: SeekingAlpha at 2017-12-04 10:51:46:000

In the past 52-weeks, shares of Acadia Pharmaceuticals (NASDAQ: ACAD ), a bioscience firm, focusing on the development and commercialization of therapeutics to treat central nervous system disorders increased by $2.12 to trade at $30.16 for 7% profits (as of Dec. 1, 2017). Despite the modest g… read more...

Can Acadia Pharmaceuticals Be A Prudent Bet For Long-Term Investors?

via: SeekingAlpha at 2017-12-04 10:51:46:000

Can Acadia Pharmaceuticals Be A Prudent Bet For Long-Term Investors?

via: SeekingAlpha at 2017-12-04 10:51:46:000

Can Acadia Pharmaceuticals Be A Prudent Bet For Long-Term Investors?

via: SeekingAlpha at 2017-12-04 10:51:46:000

Can Acadia Pharmaceuticals Be A Prudent Bet For Long-Term Investors?

via: SeekingAlpha at 2017-12-04 10:51:46:000

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor

Data provided for free by IEX

ACAD

ACADIA Pharmaceuticals Inc.

Earnings

Stats

Daily Insider Ratings Round Up 12/4/18

Daily Insider Ratings Round Up 12/4/18

Daily Insider Ratings Round Up 12/4/18

Acadia: Poised To Turn

Acadia: Poised To Turn

ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Acadia up 13% premarket on Baker Bros. stake

Acadia up 13% premarket on Baker Bros. stake

ACADIA Pharmaceuticals prices equity offering

ACADIA Pharmaceuticals prices equity offering

ACADIA Pharmaceuticals Prices Public Offering of Common Stock

ACADIA Pharmaceuticals Prices Public Offering of Common Stock

ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock

ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock

Acadia Pharmaceuticals Is A Promising Buy In 2018

Acadia Pharmaceuticals Is A Promising Buy In 2018

Acadia Pharmaceuticals Is A Promising Buy In 2018

Leerink sees 34% upside in Allergan in premarket analyst action

Leerink sees 34% upside in Allergan in premarket analyst action

Leerink sees 34% upside in Allergan in premarket analyst action

ACADIA Pharmaceuticals Inc. 2018 Q3 - Results - Earnings Call Slides

ACADIA Pharmaceuticals Inc. 2018 Q3 - Results - Earnings Call Slides

ACADIA Pharmaceuticals Inc. 2018 Q3 - Results - Earnings Call Slides

ACADIA Pharmaceuticals Inc. 2018 Q3 - Results - Earnings Call Slides

ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q3 2018 Results - Earnings Call Transcript

ACADIA Pharma beats by $0.08, beats on revenue

ACADIA Pharma beats by $0.08, beats on revenue

ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results

ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results

A Migrating Biotech Bear

A Migrating Biotech Bear

Notable earnings after Tuesday's close

Services, Consumer and Technology earnings lift futures higher

Services, Consumer and Technology earnings lift futures higher

Services, Consumer and Technology earnings lift futures higher

ACADIA Pharma up 11% premarket on positive mid-stage pimavanserin data in MDD

ACADIA Pharma up 11% premarket on positive mid-stage pimavanserin data in MDD

ACADIA Pharma up 11% premarket on positive mid-stage pimavanserin data in MDD

ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)

ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)

ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)

ACADIA Pharmaceuticals Announces Executive Leadership Change

ACADIA Pharmaceuticals Announces Executive Leadership Change

This Stock Reset Requires Patience

This Stock Reset Requires Patience

Acadia Pharmaceuticals: Continued Upside Ahead Through Sales Growth And Clinical Catalysts

Acadia Pharmaceuticals: Continued Upside Ahead Through Sales Growth And Clinical Catalysts

Acadia Pharmaceuticals: Continued Upside Ahead Through Sales Growth And Clinical Catalysts

ACADIA Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 6, 2018

Biotech Stocks Bloodied&#xA0;But Can Now Drive M&A

Biotech Stocks Bloodied&#xA0;But Can Now Drive M&A

Biotech Stocks Bloodied&#xA0;But Can Now Drive M&A

Biotech Stocks Bloodied&#xA0;But Can Now Drive M&A

ACADIA Pharmaceuticals (ACAD) Presents At Cantor Global Healthcare Conference - Slideshow

ACADIA Pharmaceuticals (ACAD) Presents At Cantor Global Healthcare Conference - Slideshow

ACADIA Pharmaceuticals (ACAD) Presents At Cantor Global Healthcare Conference - Slideshow

Acadia's Big Scores

Acadia's Big Scores

Acadia's Big Scores

ACADIA Pharmaceuticals Announces Executive Appointments to Lead Medical Affairs and Science

Daily Insider Ratings Round Up 9/24/18

Acadia Survives CNN 'Bear Attack'

ACADIA Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference on October 2, 2018

Acadia Receives A Rubber Stamp From FDA On Nuplazid Risk-Benefit Profile

Acadia Receives A Rubber Stamp From FDA On Nuplazid Risk-Benefit Profile

Acadia Receives A Rubber Stamp From FDA On Nuplazid Risk-Benefit Profile

Acadia Receives A Rubber Stamp From FDA On Nuplazid Risk-Benefit Profile

Premarket Gainers as of 9:05 am

Premarket Gainers as of 9:05 am

Premarket Gainers as of 9:05 am

Premarket Gainers as of 9:05 am

FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID&#xAE; (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson's Disease Psychosis

Acadia Pharma up 12% on favorable FDA analysis on Nuplazid

Biotech Stocks Bloodied But Can Now Drive M&A

Biotech Stocks Bloodied But Can Now Drive M&A

Biotech Stocks Bloodied But Can Now Drive M&A

Biotech Stocks Bloodied But Can Now Drive M&A

FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson's Disease Psychosis